Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 333

1.

A tripartite cooperative mechanism confers resistance of the protein kinase A catalytic subunit to dephosphorylation.

Chan TO, Armen RS, Yadav S, Shah S, Zhang J, Tiegs BC, Keny N, Blumhof B, Deshpande DA, Rodeck U, Penn RB.

J Biol Chem. 2020 Jan 21. pii: jbc.RA119.010004. doi: 10.1074/jbc.RA119.010004. [Epub ahead of print]

2.

Reply to Letter to the Editor: "Bnip3 as a potential target to treat airway smooth muscle remodeling in asthma?"

Pan S, Deshpande DA.

Am J Physiol Lung Cell Mol Physiol. 2020 Jan 1;318(1):L213-L214. doi: 10.1152/ajplung.00470.2019. No abstract available.

PMID:
31910034
3.

Increased expression of desmin and vimentin reduces bladder smooth muscle contractility via JNK2.

Javed E, Thangavel C, Frara N, Singh J, Mohanty I, Hypolite J, Birbe R, Braverman AS, Den RB, Rattan S, Zderic SA, Deshpande DA, Penn RB, Ruggieri MR Sr, Chacko S, Boopathi E.

FASEB J. 2020 Feb;34(2):2126-2146. doi: 10.1096/fj.201901301R. Epub 2019 Dec 16.

PMID:
31909533
4.

Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics.

Srivastava S, Deshpande D, Magombedze G, van Zyl J, Cirrincione K, Martin K, Bendet P, Berg A, Hanna D, Romero K, Hermann D, Gumbo T.

J Antimicrob Chemother. 2020 Feb 1;75(2):392-399. doi: 10.1093/jac/dkz460.

5.

Bnip3 regulates airway smooth muscle cell focal adhesion and proliferation.

Pan S, Shah SD, Panettieri RA Jr, Deshpande DA.

Am J Physiol Lung Cell Mol Physiol. 2019 Dec 1;317(6):L758-L767. doi: 10.1152/ajplung.00224.2019. Epub 2019 Sep 11.

PMID:
31509440
6.

Bitter Taste Receptors: an Answer to Comprehensive Asthma Control?

Nayak AP, Villalba D, Deshpande DA.

Curr Allergy Asthma Rep. 2019 Sep 5;19(10):48. doi: 10.1007/s11882-019-0876-0. Review.

7.

Diacylglycerol kinase ζ promotes allergic airway inflammation and airway hyperresponsiveness through distinct mechanisms.

Singh BK, Lu W, Schmidt Paustian AM, Ge MQ, Koziol-White CJ, Flayer CH, Killingbeck SS, Wang N, Dong X, Riese MJ, Deshpande DA, Panettieri RA Jr, Haczku A, Kambayashi T.

Sci Signal. 2019 Sep 3;12(597). pii: eaax3332. doi: 10.1126/scisignal.aax3332.

8.

Bitter Taste Receptors for Asthma Therapeutics.

Nayak AP, Shah SD, Michael JV, Deshpande DA.

Front Physiol. 2019 Jul 16;10:884. doi: 10.3389/fphys.2019.00884. eCollection 2019.

9.

Effects of ATP-competitive and function-selective ERK inhibitors on airway smooth muscle cell proliferation.

Defnet AE, Huang W, Polischak S, Yadav SK, Kane MA, Shapiro P, Deshpande DA.

FASEB J. 2019 Oct;33(10):10833-10843. doi: 10.1096/fj.201900680R. Epub 2019 Jul 26.

PMID:
31266368
10.

Synaptic FUS Localization During Motoneuron Development and Its Accumulation in Human ALS Synapses.

Deshpande D, Higelin J, Schoen M, Vomhof T, Boeckers TM, Demestre M, Michaelis J.

Front Cell Neurosci. 2019 Jun 12;13:256. doi: 10.3389/fncel.2019.00256. eCollection 2019.

11.

Specificity of NHERF1 regulation of GPCR signaling and function in human airway smooth muscle.

Pera T, Tompkins E, Katz M, Wang B, Deshpande DA, Weinman EJ, Penn RB.

FASEB J. 2019 Aug;33(8):9008-9016. doi: 10.1096/fj.201900323R. Epub 2019 May 1.

PMID:
31042404
12.

Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.

Ruth MM, Magombedze G, Gumbo T, Bendet P, Sangen JJN, Zweijpfenning S, Hoefsloot W, Pennings L, Koeken VACM, Wertheim HFL, Lee PS, van Ingen J, Deshpande D.

J Antimicrob Chemother. 2019 Jul 1;74(7):1952-1961. doi: 10.1093/jac/dkz143.

PMID:
31039251
13.

Once-a-week tigecycline for the treatment of drug-resistant TB.

Deshpande D, Magombedze G, Srivastava S, Bendet P, Lee PS, Cirrincione KN, Martin KR, Dheda K, Gumbo T.

J Antimicrob Chemother. 2019 Jun 1;74(6):1607-1617. doi: 10.1093/jac/dkz061.

PMID:
30820554
14.

Regulation of ovarian cancer G protein-coupled receptor-1 expression and signaling.

Nayak AP, Pera T, Deshpande DA, Michael JV, Liberato JR, Pan S, Tompkins E, Morelli HP, Yi R, Wang N, Penn RB.

Am J Physiol Lung Cell Mol Physiol. 2019 May 1;316(5):L894-L902. doi: 10.1152/ajplung.00426.2018. Epub 2019 Feb 6.

PMID:
30724097
15.

NF-κB and GATA-Binding Factor 6 Repress Transcription of Caveolins in Bladder Smooth Muscle Hypertrophy.

Thangavel C, Gomes CM, Zderic SA, Javed E, Addya S, Singh J, Das S, Birbe R, Den RB, Rattan S, Deshpande DA, Penn RB, Chacko S, Boopathi E.

Am J Pathol. 2019 Apr;189(4):847-867. doi: 10.1016/j.ajpath.2018.12.013. Epub 2019 Jan 30.

PMID:
30707892
16.

Mitochondrial regulation of airway smooth muscle functions in health and pulmonary diseases.

Pan S, Conaway S Jr, Deshpande DA.

Arch Biochem Biophys. 2019 Mar 15;663:109-119. doi: 10.1016/j.abb.2019.01.002. Epub 2019 Jan 8. Review.

PMID:
30629957
17.

Cooperativity of E-prostanoid receptor subtypes in regulating signaling and growth inhibition in human airway smooth muscle.

Michael JV, Gavrila A, Nayak AP, Pera T, Liberato JR, Polischak SR, Shah SD, Deshpande DA, Penn RB.

FASEB J. 2019 Apr;33(4):4780-4789. doi: 10.1096/fj.201801959R. Epub 2019 Jan 2.

PMID:
30601680
18.

Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Martin KR, Athale S, van Zyl J, Antiabong J, Koeuth T, Lee PS, Dheda K, Gumbo T.

J Infect Dis. 2019 Feb 23;219(6):975-985. doi: 10.1093/infdis/jiy587.

PMID:
30597040
19.

Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!

Srivastava S, Deshpande D, Magombedze G, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S359-S364. doi: 10.1093/cid/ciy627.

20.

Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.

Magombedze G, Pasipanodya JG, Srivastava S, Deshpande D, Visser ME, Chigutsa E, McIlleron H, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S349-S358. doi: 10.1093/cid/ciy623.

21.

The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.

Srivastava S, Deshpande D, Nuermberger E, Lee PS, Cirrincione K, Dheda K, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S336-S341. doi: 10.1093/cid/ciy626.

22.

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, Lee PS, Bhavnani SM, Ambrose PG, Thwaites G, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S293-S302. doi: 10.1093/cid/ciy611.

23.

d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Deshpande D, Alffenaar JC, Köser CU, Dheda K, Chapagain ML, Simbar N, Schön T, Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S, Ogarkov O, Pholwat S, Houpt ER, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624.

24.

Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Bendet P, Koeuth T, Bhavnani SM, Ambrose PG, Smythe W, McIlleron H, Thwaites G, Gumusboga M, Van Deun A, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S274-S283. doi: 10.1093/cid/ciy618.

25.

Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.

Pasipanodya JG, Smythe W, Merle CS, Olliaro PL, Deshpande D, Magombedze G, McIlleron H, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S284-S292. doi: 10.1093/cid/ciy610.

26.

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Srivastava S, Bendet P, Koeuth T, Lee PS, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S317-S326. doi: 10.1093/cid/ciy609.

27.

Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.

Deshpande D, Srivastava S, Nuermberger E, Koeuth T, Martin KR, Cirrincione KN, Lee PS, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S342-S348. doi: 10.1093/cid/ciy612.

28.

Autophagy Activation in Asthma Airways Remodeling.

McAlinden KD, Deshpande DA, Ghavami S, Xenaki D, Sohal SS, Oliver BG, Haghi M, Sharma P.

Am J Respir Cell Mol Biol. 2019 May;60(5):541-553. doi: 10.1165/rcmb.2018-0169OC.

PMID:
30383396
29.

An Audit for Radiotherapy Planning and Treatment Errors From a Low-Middle-Income Country Centre.

Agarwal JP, Krishnatry R, Panda G, Pathak R, Vartak C, Kinhikar RA, James S, Khobrekar SV, Shrivastava SK, D'Cruz AK, Deshpande DD.

Clin Oncol (R Coll Radiol). 2019 Jan;31(1):e67-e74. doi: 10.1016/j.clon.2018.09.008. Epub 2018 Oct 12.

PMID:
30322681
30.

Impact of inter-observer variations in target volume delineation on dose volume indices for accelerated partial breast irradiation with multi-catheter interstitial brachytherapy.

Upreti RR, Budrukkar A, Upreti U, Wadasadawala T, Misra S, Gurram L, Pathak R, Deshpande DD.

Radiother Oncol. 2018 Oct;129(1):173-179. doi: 10.1016/j.radonc.2018.06.029. Epub 2018 Jul 6.

PMID:
30318170
31.

MicroRNA-638 inhibits human airway smooth muscle cell proliferation and migration through targeting cyclin D1 and NOR1.

Wang H, Yao H, Yi B, Kazama K, Liu Y, Deshpande D, Zhang J, Sun J.

J Cell Physiol. 2018 Jan;234(1):369-381. doi: 10.1002/jcp.26930. Epub 2018 Aug 4. Review.

32.

Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS.

Helferich AM, Brockmann SJ, Reinders J, Deshpande D, Holzmann K, Brenner D, Andersen PM, Petri S, Thal DR, Michaelis J, Otto M, Just S, Ludolph AC, Danzer KM, Freischmidt A, Weishaupt JH.

Cell Mol Life Sci. 2018 Dec;75(23):4301-4319. doi: 10.1007/s00018-018-2873-1. Epub 2018 Jul 20.

PMID:
30030593
33.

Apoptosis signal-regulating kinase 1 inhibition attenuates human airway smooth muscle growth and migration in chronic obstructive pulmonary disease.

Eapen MS, Kota A, Vindin H, McAlinden KD, Xenaki D, Oliver BG, Deshpande DA, Sohal SS, Sharma P.

Clin Sci (Lond). 2018 Jul 31;132(14):1615-1627. doi: 10.1042/CS20180398. Print 2018 Jul 31.

34.

New targets for resolution of airway remodeling in obstructive lung diseases.

Nayak AP, Deshpande DA, Penn RB.

F1000Res. 2018 May 30;7. pii: F1000 Faculty Rev-680. doi: 10.12688/f1000research.14581.1. eCollection 2018. Review.

35.

Implementation of failure mode and effective analysis for high dose rate brachytherapy at Tata Memorial Hospital, Mumbai, India.

Swamidas J, Khanna N, Mahantshetty U, Somesan V, Deshpande DD, Shrivastava SK.

Cancer Radiother. 2018 Jun;22(4):334-340. doi: 10.1016/j.canrad.2018.05.001. Epub 2018 May 30.

PMID:
29859762
36.

Novel splice-site variant of UCHL1 in an Indian family with autosomal recessive spastic paraplegia-79.

Das Bhowmik A, Patil SJ, Deshpande DV, Bhat V, Dalal A.

J Hum Genet. 2018 Aug;63(8):927-933. doi: 10.1038/s10038-018-0463-6. Epub 2018 May 7.

PMID:
29735986
37.

Monte Carlo Investigation of Photon Beam Characteristics and its Variation with Incident Electron Beam Parameters for Indigenous Medical Linear Accelerator.

Mishra S, Dixit PK, Selvam TP, Yavalkar SS, Deshpande DD.

J Med Phys. 2018 Jan-Mar;43(1):1-8. doi: 10.4103/jmp.JMP_125_17.

38.

Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle.

Thangavel C, Perepelyuk M, Boopathi E, Liu Y, Polischak S, Deshpande DA, Rafiq K, Dicker AP, Knudsen KE, Shoyele SA, Den RB.

Mol Pharm. 2018 May 7;15(5):1778-1790. doi: 10.1021/acs.molpharmaceut.7b01024. Epub 2018 Apr 4.

39.

Commissioning and validation of commercial deformable image registration software for adaptive contouring.

Jamema SV, Phurailatpam R, Paul SN, Joshi K, Deshpande DD.

Phys Med. 2018 Mar;47:1-8. doi: 10.1016/j.ejmp.2018.01.013. Epub 2018 Feb 9.

PMID:
29609810
40.

CD38/cADPR Signaling Pathway in Airway Disease: Regulatory Mechanisms.

Deshpande DA, Guedes AGP, Graeff R, Dogan S, Subramanian S, Walseth TF, Kannan MS.

Mediators Inflamm. 2018 Feb 7;2018:8942042. doi: 10.1155/2018/8942042. eCollection 2018. Review.

41.

Magnetic Resonance Image Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer: An Experience From a Tertiary Cancer Center in a Low and Middle Income Countries Setting.

Mahantshetty U, Krishnatry R, Hande V, Jamema S, Ghadi Y, Engineer R, Chopra S, Gurram L, Deshpande D, Shrviastava S.

Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):608-617. doi: 10.1016/j.ijrobp.2017.06.010. Epub 2017 Jun 20.

PMID:
29280456
42.

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.

Deshpande D, Srivastava S, Bendet P, Martin KR, Cirrincione KN, Lee PS, Pasipanodya JG, Dheda K, Gumbo T.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02232-17. doi: 10.1128/AAC.02232-17. Print 2018 Feb.

43.

Familial choreoathetosis due to novel heterozygous mutation in PDE10A.

Narayanan DL, Deshpande D, Das Bhowmik A, Varma DR, Dalal A.

Am J Med Genet A. 2018 Jan;176(1):146-150. doi: 10.1002/ajmg.a.38507. Epub 2017 Nov 12.

PMID:
29130591
44.

Biased signaling of the proton-sensing receptor OGR1 by benzodiazepines.

Pera T, Deshpande DA, Ippolito M, Wang B, Gavrila A, Michael JV, Nayak AP, Tompkins E, Farrell E, Kroeze WK, Roth BL, Panettieri RA Jr, Benovic JL, An SS, Dulin NO, Penn RB.

FASEB J. 2018 Feb;32(2):862-874. doi: 10.1096/fj.201700555R. Epub 2018 Jan 4.

45.

Homeostatic nuclear RAGE-ATM interaction is essential for efficient DNA repair.

Kumar V, Fleming T, Terjung S, Gorzelanny C, Gebhardt C, Agrawal R, Mall MA, Ranzinger J, Zeier M, Madhusudhan T, Ranjan S, Isermann B, Liesz A, Deshpande D, Häring HU, Biswas SK, Reynolds PR, Hammes HP, Peperkok R, Angel P, Herzig S, Nawroth PP.

Nucleic Acids Res. 2017 Oct 13;45(18):10595-10613. doi: 10.1093/nar/gkx705.

46.

Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease.

Pasipanodya JG, Ogbonna D, Deshpande D, Srivastava S, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i3-i19. doi: 10.1093/jac/dkx311. Review.

PMID:
28922813
47.

A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting.

Deshpande D, Srivastava S, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i54-i60. doi: 10.1093/jac/dkx309.

PMID:
28922811
48.

A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease.

Srivastava S, Deshpande D, Sherman CM, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i43-i47. doi: 10.1093/jac/dkx308.

PMID:
28922810
49.

A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease.

Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i48-i53. doi: 10.1093/jac/dkx307.

PMID:
28922809
50.

The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent.

Deshpande D, Srivastava S, Chapagain ML, Lee PS, Cirrincione KN, Pasipanodya JG, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i36-i42. doi: 10.1093/jac/dkx306.

PMID:
28922808

Supplemental Content

Loading ...
Support Center